864266-28-4

Basic information

• Product Name: (Z)-6-bromonicotinaldehyde oxime
• Synonyms: (Z)-6-bromonicotinaldehyde oxime;6-bromonicotinaldehydeoxime;6-Bromo-pyridine-3-carbaldehyde oxime
• CAS NO: 864266-28-4
• Molecular Formula: C₆H₅BrN₂O
• Molecular Weight: 201.023
• Mol File: 864266-28-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (Z)-6-bromonicotinaldehyde oxime(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-6-bromonicotinaldehyde oxime(864266-28-4)
• EPA Substance Registry System: (Z)-6-bromonicotinaldehyde oxime(864266-28-4)

Safety Data

• Hazardous Substances Data: 864266-28-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
(Z)-6-bromonicotinaldehyde oxime is used as a precursor in the synthesis of various organic compounds, contributing to the development of new chemical entities and materials.
Used in Drug Development:
(Z)-6-bromonicotinaldehyde oxime is used as a potential candidate in drug development due to its studied biological activities, such as anti-cancer and anti-inflammatory properties. Its potential to modulate various signaling pathways and exhibit synergistic effects with conventional chemotherapeutic drugs makes it a promising agent for therapeutic applications.
Used in Metal Ion Coordination Chemistry:
(Z)-6-bromonicotinaldehyde oxime is used as a chelating agent in metal ion coordination chemistry, where it can form stable complexes with metal ions. This application is valuable in various fields, including environmental remediation, catalysis, and the development of new materials with specific properties.

Upstream product

• 122306-01-8 2-bromo-5-(hydroxymethyl)pyridine 
• 149806-06-4 6-bromonicotinaldehyde 

Downstream Products

• 139585-70-9 2-bromo-5-cyanopyridine 

Relevant articles and documents

Identification of triazolopyridine derivatives as a new class of AhR agonists and evaluation of anti-psoriasis effect in a mouse model

The aryl hydrocarbon receptor (AhR), a ligand-dependent transcription factor, can regulate the immune balance of Th17/22 and Treg cells, which plays an important role in the development and maintenance of the skin barrier. We herein report the discovery of triazolopyridine derivatives as a new class of AhR agonists. Structure-activity relationship analyses led to the identification of the most active compound, 6-bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine (12a), with an EC50 (50% effective concentration) value of 0.03 nM. Compound 12a could induce rapid nuclear enrichment of AhR, trigger the transcription of downstream genes and promote skin barrier repair. Topical or oral administration of 12a could significantly alleviate imiquimod (IMQ)-induced psoriasis-like skin lesion. Considering the excellent in vivo anti-psoriasis activity as well as good pharmacokinetic properties, 12a could be a promising lead compound for drug discovery against psoriasis, and deserving further investigation.

A Transition-Metal-Free One-Pot Cascade Process for Transformation of Primary Alcohols (RCH2OH) to Nitriles (RCN) Mediated by SO2F2

A new transition-metal-free one-pot cascade process for the direct conversion of alcohols to nitriles was developed without introducing an “additional carbon atom”. This protocol allows transformations of readily available, inexpensive, and abundant alcohols to highly valuable nitriles.

Synthesis of Novel 3-aryl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene Derivatives and Their Biological Evaluation Against Protein Tyrosine Phosphatase 1B

A series of novel 3-aryl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene derivatives were designed, synthesized, and evaluated as a new class of inhibitors against protein tyrosine phosphatase 1B. Among them, compound 6f displayed moderate inhibitory activity with IC50 of 2.87 ± 0.24 μm and can be used as a novel lead compound for the design of inhibitors of protein tyrosine phosphatase 1B. A series of novel 3-aryl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene derivatives were designed, synthesized, and evaluated as a new class of inhibitors against PTP1B. Among them, compound 6f displayed moderate inhibitory activity with IC50 of 2.87 ± 0.24 μm and can be used as a novel lead compound for the design of inhibitors of PTP1B.

Regioselective synthesis of 2,6-dimethyl-3,5-bis[(3-aryl-5-trifluoromethyl) -isoxazol-4-carbonyl]-pyridine derivatives

Ethyl 4,4,4-trifluoro-3-oxo-butyrate reacted with 2,6-dimethyl-3,5- diacetyl-pyridine 1 in the presence of NaOC2H5 at 0°C to give 2,6-dimethyl-3,5-bis(4,4,4-trifluoro-1,3-oxo-butyl)-pyridine (2a) in good yield. Cyclization reaction o